Recently, the protein hnRNPK has emerged as an important player in carcinogenesis process.
The therapeutic strategies targeted on the protein hnRNPK are very limited.
The effect of small molecules on hnRNPK protein hasn't been reported in cervical cancer.
Our study indicated that NJXA showed antitumor effect in vitro and in vivo by targeting hnRNPK protein.
NJXA is especially applicable as a potential candidate for treating cervical cancer with abnormally high hnRNPK expression.